therapeutic autologous dendritic cells

Daiichi and Merck’s Lung Cancer ADC Achieves 48% Response Rate in Pivotal Trial

1 week ago talkbio0Tagged Accelerated, Antibody-Drug Conjugates, Approved, Breakthrough Therapy, CD276 gene, Co., Daiichi, Deruxtecan, Frequency of Responses, IDeate-Lung01, Identifier, ifinatamab, Overall Survival, Progression-Free Survival, Sankyo, Small cell carcinoma of lung, therapeutic autologous dendritic cells, United States Food and Drug Administration

Daiichi Sankyo; Merck & Co.; ifinatamab deruxtecan; I-DXd; B7-H3; antibody-drug conjugate; ADC; small cell lung cancer; SCLC; IDeate-Lung01; objective response rate; accelerated approval; progression-free survival; overall survival; FDA Breakthrough Therapy Designation

CytomX Continues Phase I ADC Study After Patient Death

1 month ago talkbio0Tagged ADC, Clinical Trials, Colorectal Carcinoma, CX-2051, CytomX, Kidney Failure, Acute, Patient Death, Phase I, Safety, therapeutic autologous dendritic cells, United States Food and Drug Administration

CytomX; CX-2051; Phase I; ADC; colorectal cancer; patient death; acute kidney injury; clinical trial; safety; FDA; trial continuation

Minghui Raises $131M to Advance PD-1xVEGF Bispecific Antibody Program

1 month ago talkbio0Tagged Chinese biotech, Clinical Development, Inhibitor, Janus kinase, Minghui, Neoplasms, PD-1xVEGF bispecific, pre-IPO ', therapeutic autologous dendritic cells, trials

Minghui; Chinese biotech; PD-1xVEGF bispecific; fundraising; pre-IPO; ADC trials; JAK inhibitor; oncology; clinical development

NextCure Partners with Simcere for Novel ADC in $745M Deal

3 months ago talkbio0Tagged ADC, Antibody-Drug Conjugates, CDH6 gene, cellular targeting, NextCure, SIM0505, Simcere, therapeutic autologous dendritic cells

NextCure; Simcere; Antibody-Drug Conjugate; ADC; SIM0505; CDH6 Targeting

ADC Therapeutics Cuts 30% of Workforce, Closes UK R&D Site Amid Strategic Shift

3 months ago talkbio0Tagged Antibody-Drug Conjugates, facility closure, layoffs, preclinical programs, R&D, restructuring, Solid Neoplasm, therapeutic autologous dendritic cells, UK, Zynlonta

ADC Therapeutics; layoffs; UK facility closure; biotech restructuring; R&D; antibody-drug conjugates; solid tumors; Zynlonta; preclinical programs

Merck Advances Middle Dose of ROR1 ADC in Relapsed/Refractory DLBCL After Safety Review

4 months ago talkbio0Tagged Adverse event, Clinical Trials, Diffuse Large B-Cell Lymphoma, Merck, middle dose, Relapsing course, ROR1 protein, human, Safety, therapeutic autologous dendritic cells, Unresponsive to Treatment, vedotin, waveLINE-003, Zilovertamab

Merck; ROR1; ADC; zilovertamab vedotin; middle dose; 1.75 mg/kg; relapsed DLBCL; refractory DLBCL; WaveLINE-003; safety; adverse events; clinical trial; ASCO 2025

Astellas Secures $1.34B Licensing Deal for CLDN18.2-Targeted ADC with Evopoint Biosciences

4 months ago talkbio0Tagged Antibody-Drug Conjugates, Astellas, Evopoint Biosciences, Licensing Deal, Neoplasms, therapeutic autologous dendritic cells

Astellas; Evopoint Biosciences; CLDN18.2; antibody-drug conjugate; ADC; licensing deal; oncology; XNW27011

Merck, Daiichi Sankyo Withdraw FDA Application for HER3-Targeting ADC After Survival Endpoint Miss

4 months ago talkbio0Tagged Application procedure, Clinical Trials, Daiichi, Deruxtecan, HER3, Merck, Non-Small Cell Lung Carcinoma, Overall Survival, patritumab, Sankyo, therapeutic autologous dendritic cells, United States Food and Drug Administration, Withdraw (activity)

Merck; Daiichi Sankyo; patritumab deruxtecan; HER3 ADC; FDA application; non-small cell lung cancer; clinical trial; overall survival; application withdrawal

AbbVie Advances Solid Tumor Program with FDA Approval of Emrelis for Lung Cancer

4 months ago talkbio0Tagged AbbVie, Accelerated, ADC, Approved, Emrelis, Malignant neoplasm of lung, MET protein, human, Non-Small Cell Lung Carcinoma, Protein Overexpression, Solid Neoplasm, Telisotuzumab, therapeutic autologous dendritic cells, United States Food and Drug Administration, vedotin-tllv

AbbVie; Emrelis; FDA Approval; ADC; solid tumor; lung cancer; non-small cell lung cancer; c-Met overexpression; telisotuzumab vedotin-tllv; accelerated approval

Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics

6 months ago talkbio0Tagged Antibody-Drug Conjugates, biobucks, New, OBT, Oxford BioTherapeutics, Partnership, Roche (company), therapeutic autologous dendritic cells

OBT, therapeutic autologous dendritic cells, Roche (company), Partnership, Oxford BioTherapeutics, Antibody-Drug Conjugates, biobucks, New